Author + information
- Received May 11, 2016
- Accepted June 13, 2016
- Published online August 23, 2016.
- Matthew H. Vorsanger, MDa,
- Pritha Subramanyam, MDb,
- Howard S. Weintraub, MDa,
- Steven H. Lamm, MDc,
- James A. Underberg, MDc,
- Eugenia Gianos, MDa,
- Ira J. Goldberg, MDd and
- Arthur Z. Schwartzbard, MDa,∗ ()
- aDivision of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, New York
- bDivision of General Internal Medicine, Department of Medicine, The Mount Sinai Hospital, New York, New York
- cDivision of General Internal Medicine, Department of Medicine, New York University Langone Medical Center, New York, New York
- dDepartment of Medicine, Division of Endocrinology, New York University Langone Medical Center, New York, New York
- ↵∗Reprint requests and correspondence:
Dr. Arthur Schwartzbard, Clinical Lipid Research, NYU Center for Prevention of Cardiovascular Disease, Department of Medicine (Cardiology), 530 First Avenue, Suite 4F, New York, New York 10016.
The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
Dr. Weintraub has received research funding from Amarin and Sanofi; has served as a consultant for Amgen, Sanofi, and Gilead; and has been a speaker for Gilead, Amgen, and AstraZeneca. Dr. Lamm has received consulting fees from Eisai, Alkermes, Takeda, Abbvie, and Endo; and has served on the Speakers Bureau for Eisai. Dr. Underberg has received Speakers Bureau honoraria from AstraZeneca, Regeneron, Amgen, Sanofi, Genzyme, Merck, Synageva, Alexion, and Aegerion; has served as a consultant for Aegerion, AstraZeneca, Eli Lilly, Sanofi, Alexion, Synageva, Amgen, Recombine, and Amarin; has served on the advisory boards for Akcea, Amgen, Sanofi, Eli Lilly, Genzyme, Regeneron, Astra Zeneca, and Aegerion; and has been involved in clinical research for Pfizer, Genzyme, and Aegerion. Dr. Goldberg has consulted for Amgen, Sanofi, and Merck; and has received research support from Janssen and ISIS Pharmaceuticals. Dr. Schwartzbard has received research support to New York University from Merck, Pfizer, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received May 11, 2016.
- Accepted June 13, 2016.
- American College of Cardiology Foundation